Objective: This study was conducted to examine the effects of endothelin (ET)-1 and ET-3 on hepatic venules and sinusoids and to identify the subtypes of ET receptors. Method: Hepatic venules and sinusoids of anesthetized mice were observed at the edge of the liver. ET-1, ET-3 and sarafotoxin (S6c, a selective ETB receptor agonist) were applied topically over the microvasculature. Results: ET-1, ET-3 and S6c (1-100 µM, 30 µl) induced dose-dependent vasoconstriction of the portal venules, the sinusoids and the central venules. The ETs and S6c were equipotent for these microvessels. BQ-123 (a selective ETA receptor antagonist) inhibited the constrictive effects of ET-3 (not of ET-1) on the portal venules and central venules, whereas it had no inhibitory effect on the sinusoids. Conclusions: In mouse hepatic venules and sinusoids, the vasoconstriction induced by ET-1 and ET-3 was mediated mainly through the ETB receptor subtype and partly through an unknown BQ-123-sensitive ET receptor subtype in the portal and central venules, and only through the ETB receptor subtype in the sinusoids.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.